JP2010523492A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523492A5
JP2010523492A5 JP2010501048A JP2010501048A JP2010523492A5 JP 2010523492 A5 JP2010523492 A5 JP 2010523492A5 JP 2010501048 A JP2010501048 A JP 2010501048A JP 2010501048 A JP2010501048 A JP 2010501048A JP 2010523492 A5 JP2010523492 A5 JP 2010523492A5
Authority
JP
Japan
Prior art keywords
phenyl
ethyl
methyl
hydroxypyrrolidin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010501048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523492A (ja
JP5416085B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/056317 external-priority patent/WO2008121496A1/en
Publication of JP2010523492A publication Critical patent/JP2010523492A/ja
Publication of JP2010523492A5 publication Critical patent/JP2010523492A5/ja
Application granted granted Critical
Publication of JP5416085B2 publication Critical patent/JP5416085B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010501048A 2007-03-30 2008-03-07 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト Expired - Fee Related JP5416085B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92084107P 2007-03-30 2007-03-30
US60/920,841 2007-03-30
PCT/US2008/056317 WO2008121496A1 (en) 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013101705A Division JP2013173790A (ja) 2007-03-30 2013-05-13 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト

Publications (3)

Publication Number Publication Date
JP2010523492A JP2010523492A (ja) 2010-07-15
JP2010523492A5 true JP2010523492A5 (https=) 2011-05-12
JP5416085B2 JP5416085B2 (ja) 2014-02-12

Family

ID=39795494

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010501048A Expired - Fee Related JP5416085B2 (ja) 2007-03-30 2008-03-07 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト
JP2013101705A Pending JP2013173790A (ja) 2007-03-30 2013-05-13 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013101705A Pending JP2013173790A (ja) 2007-03-30 2013-05-13 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト

Country Status (19)

Country Link
US (2) US7960429B2 (https=)
EP (3) EP2136801B1 (https=)
JP (2) JP5416085B2 (https=)
KR (2) KR101208326B1 (https=)
CN (2) CN102641265A (https=)
AU (1) AU2008232954A1 (https=)
BR (1) BRPI0809651A2 (https=)
CA (1) CA2682608A1 (https=)
CY (1) CY1113317T1 (https=)
DK (1) DK2136801T3 (https=)
ES (1) ES2393815T3 (https=)
HR (1) HRP20120798T1 (https=)
IL (1) IL201226A0 (https=)
MX (1) MX2009010409A (https=)
PL (1) PL2136801T3 (https=)
PT (1) PT2136801E (https=)
RU (1) RU2441655C2 (https=)
SI (1) SI2136801T1 (https=)
WO (1) WO2008121496A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682608A1 (en) 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
CA3178035A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
JP6410641B2 (ja) 2015-03-04 2018-10-24 ローム株式会社 ワイヤレス送電装置、異物検出方法、充電器
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
ES2906979T3 (es) 2016-12-21 2022-04-21 Tioga Pharmaceuticals Inc Formulaciones farmacéuticas sólidas de asimadolina
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
AU2021236662A1 (en) * 2020-03-18 2022-11-10 Cara Therapeutics, Inc. Oligosaccharide formulations of kappa opioid receptor agonists
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline
JP7464744B2 (ja) * 2020-10-20 2024-04-09 セトラスホールディングス株式会社 診療支援装置、診療支援方法、診療支援プログラム及び診療支援システム
WO2022155332A1 (en) * 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
US4663343A (en) 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
GB8601796D0 (en) 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
EP0330467A1 (en) 1988-02-23 1989-08-30 Glaxo Group Limited Heterocyclic compounds
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5389686A (en) 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE3916663A1 (de) 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
CA2021817C (en) 1989-07-24 2000-09-26 William J. Mork Upholstered article of furniture with interchangeable seating module
US5322848A (en) 1989-11-24 1994-06-21 Dr. Lo Zembeletti S.P.A. N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20010051181A1 (en) 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
AR019727A1 (es) 1998-06-30 2002-03-13 Takeda Chemical Industries Ltd Composicion farmaceutica
DE19849650A1 (de) * 1998-10-29 2000-05-04 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS)
PT1033364E (pt) 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
US20020025948A1 (en) 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
WO2003048113A1 (en) 2001-11-30 2003-06-12 Sepracor Inc. Tramadol analogs and uses thereof
WO2003097051A2 (en) * 2002-05-17 2003-11-27 Merck Patent Gmbh Use of compounds that are effective as selective opiate receptor modulators
US7164021B2 (en) 2002-09-18 2007-01-16 The Curators Of The University Of Missouri Opiate analogs selective for the δ-opioid receptor
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
JP2007501866A (ja) 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
EP1680115A1 (en) * 2003-10-30 2006-07-19 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CA2682608A1 (en) * 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Similar Documents

Publication Publication Date Title
JP2010523492A5 (https=)
RU2009140042A (ru) Агонисты каппа-опиоидов для лечения синдрома раздраженного кишечника с преобладанием диареи и перемежающегося синдрома раздраженного кишечника
JP2006506378A5 (https=)
JP2010518122A5 (https=)
JP2020517719A5 (https=)
JP2009536176A5 (https=)
HRP20250615T1 (hr) Tradipitant za upotrebu u liječenju gastropareze
JP2010525084A5 (https=)
JP2009280621A5 (https=)
ES3009607T3 (en) Nk-1 antagonist compositions and methods for use in treating depression
JP2010522137A5 (https=)
TW202341996A (zh) 用於治療腸胃疾病或病狀之神經活性類固醇
JP2012531402A5 (https=)
JP2008533127A5 (https=)
Palaniyappan et al. Combining antidepressants: a review of evidence
JP2011527687A5 (https=)
McCarberg Overview and treatment of opioid-induced constipation
PT1359939E (pt) Composição e método para potenciar fármacos
JP2011519873A5 (https=)
JP2020531543A (ja) アマンタジン組成物、その調製、および使用方法
JP2013032308A5 (https=)
WO2023164387A1 (en) Neuroactive steroids for treatment of gastrointestinal diseases or conditions
HRP20171330T1 (hr) Postupak za proizvodnju i korištenje kopolimera natrijeve karboksimetil celuloze i gosipola
JP2023531930A5 (https=)
JP2019142774A (ja) 腸内環境改善剤